DWTX · Dogwood Therapeutics, Inc. · Metrics
$1.15
+0.00 (+0.00%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, there is substantial doubt about the Company's ability to operate as a going concern within one year after the issuance date of these condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$39.09M
Shares
33.99M
Volume · Oct 21
35.83K
Avg daily vol (3M)
69.14K
DWTX metrics
57 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.15
Market cap
$39.09M
Price action
20 metricsPrice change (1W)
-11.5%
Price change (30D)
-28.1%
Price change (3M)
-17.9%
Price change (6M)
-24.6%
Price change (YTD)
-72.4%
Price change (1Y)
-81.4%
Trailing year
Price change (5Y)
—
52-week high
$6.82
52-week low
$1.15
Change from 52-week high
-83.1%
Change from 52-week low
+0.0%
Annualized volatility
86.8%
Annualized volatility (3M)
73.9%
Beta
1.3
RSI (14D)
23.9
Price vs SMA 50
-37.0%
Price vs SMA 200
-44.2%
Avg volume (3M)
69,135
Relative volume
0.7
Average dollar volume
$126,188
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
33.99M
Valuation
12 metricsP / E (TTM)
0.4
Trailing earnings · reciprocal yield 245.2%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 174.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-92.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-14
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$38.76M
Net income (TTM)
−$36.04M
Trailing 12 months
Diluted EPS (TTM)
$2.82
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,685.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-52.7%
Return on assets
-44.8%
Debt / equity
—
Current ratio
3.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.61M
Latest balance sheet
Cash & equivalents
$9.61M
Total assets
$80.50M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$15.11M
Capital expenditures (TTM)
—
R&D (TTM)
$22.78M
SG&A (TTM)
—
Stock compensation (TTM)
$1.20M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
15
13F filer change QoQ
+2
Institutional ownership
11.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.4%
Private-fund adviser ownership
10.4%
Active holders' share change QoQ
+5.6%
Holder tenure
2.1
Price vs estimated holder cost
-42.8%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.7%
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
22 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged